Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Haisikang: Innovative drug HSK42360 tablets included in the "Childhood Anti-Tumor Drug Development Encouragement Pilot Program (Starlight Program)" pilot project
Haisike Pharmaceutical Group Co., Ltd. announced that its self-developed HSK42360 tablets were included in the “Childhood Anti-tumor Drug Development Encouragement Pilot Program (Starlight Program)” pilot project by the National Medical Products Administration’s Drug Evaluation Center on April 8, 2026. HSK42360 tablets are a targeted BRAF V600 mutation small molecule inhibitor with brain permeability, intended for use in advanced solid tumors with BRAF V600 mutations, especially in pediatric gliomas. Currently, two Phase I clinical studies are underway, targeting adult solid tumor patients and pediatric malignant brain tumor patients aged 6 years and older but under 18 years.